D.s, post-doctoral fellows and accomplished young scientists (a phenomenon known to many as Israel's "brain drain").
With chapters in New York, Los Angeles, Chicago, Toronto, Montreal, and Jerusalem, ICRF annually sponsors a grant review process conducted by an expert panel of U.S. and Canadian scientists and oncologists and modeled on the NIH grant-making process.
[1] Grants have been provided to over 20 institutions including all major hospitals, universities, and cancer research projects throughout Israel.
Breakthrough discoveries by ICRF-funded scientists have led to the development of Gleevec -used in the successful treatment of chronic myelogenous leukemia[citation needed]; Doxil - used in the treatment of breast & ovarian cancer as well as AIDS[citation needed]; p53 – a key tumor suppressor; RAD 51 which identifies the likelihood of breast cancer occurring in women who carry the BRCA 2 gene and Velcade[citation needed].
The basic research ICRF funds have led to treatments and drugs that are benefiting cancer patients around the world.